drugset / Trial / NCT07516925

A Study of Ivonescimab in People With Leiomyosarcoma

NCT07516925

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if Ivonescimab is an effective and safe treatment that causes few or mild side effects for people with advanced/unresectable leiomyosarcoma.

Timeline

Start
2026-04-01
Primary completion
2029-04
Completion
2029-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody Intravenous

Indications